Related Experiment Video
Updated: Jan 19, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer]
1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Abstract:
BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable results in advanced NSCLC patients with BRAF V600E mutation, which has been written into the National Comprehensive Cancer Network (NCCN) guidelines, severe side effects of the combination therapy are frequently observed. There isn't effective treatment strategy after drug resistance, and targeted therapy for non-V600E mutation patients is still lacking. In this paper, we summarized the researches on expression of immune markers in NSCLC patients with mutant BRAF and analyzed the studies on efficacy of immune checkpoint inhibitor (ICI), so as to provide more options for prolonging survival of the patients. .
Insights
BRAF mutations in non-small cell lung cancer (NSCLC) present challenges, but immune checkpoint inhibitors show promise. Research is exploring their efficacy, especially for patients with non-V600E mutations, to improve survival outcomes.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- BRAF gene mutations occur in 2-4% of non-small cell lung cancer (NSCLC) patients, correlating with aggressive disease and poor prognosis.
- Current treatments like BRAF and MEK inhibitors are effective for BRAF V600E mutations but have side effects and limited options post-resistance.
- Targeted therapies for non-V600E BRAF mutations in NSCLC remain underdeveloped.
Purpose of the Study:
- To review immune marker expression in NSCLC patients with BRAF mutations.
- To analyze the efficacy of immune checkpoint inhibitors (ICIs) in this patient population.
- To identify potential new treatment strategies for BRAF-mutated NSCLC.
Main Methods:
- Literature review of studies on immune marker expression in BRAF-mutated NSCLC.
- Analysis of clinical trial data on ICI efficacy in BRAF-mutated NSCLC.
- Synthesis of research findings to evaluate treatment options.
Main Results:
- The review highlights the role of immune markers in the tumor microenvironment of BRAF-mutated NSCLC.
- Preliminary data suggests potential efficacy of ICIs in specific subsets of BRAF-mutated NSCLC patients.
- Challenges include understanding resistance mechanisms and identifying predictive biomarkers for ICI response.
Conclusions:
- Immune checkpoint inhibitors represent a promising avenue for treating BRAF-mutated NSCLC, particularly non-V600E variants.
- Further research is needed to optimize ICI therapy and develop strategies to overcome drug resistance.
- Exploring combination therapies involving ICIs may enhance survival for NSCLC patients with BRAF mutations.
More Related Videos
Related Concept Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:11Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
03:363D Co-culture of Lung Cancer Cells with CAFs: An In Vitro Model System to Study Tumor Progression
04:43Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors